Stay updated on Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-29T11:43:43.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    A banner announces NIH website updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during a transition.
    Difference
    1%
    Check dated 2026-10-22T12:15:40.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2; the study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-15T13:39:07.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-08T14:06:07.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study details, indicating the resource is blocked; this is an access restriction rather than an update to the study information or page layout.
    Difference
    0.5%
    Check dated 2026-10-01T15:29:30.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, preventing access to the study record. The previously visible trial details and sponsor information are no longer accessible on this page.
    Difference
    21%
    Check dated 2026-09-24T18:07:22.000Z thumbnail image

Stay in the know with updates to Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.